24 January 2024
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies. The guideline was published in the non-profit open access journal PLOS Medicine.
Multiple Sclerosis Awareness Week – shining a light on unmet needs Vast strides have been made in multiple sclerosis (MS) treatment and care in recent years. Despite these advancements, unmet needs remain for people living with this lifelong condition that can severely impact many aspects of their lives. MS Brain Health – time matters 2024,…
News and events We are thrilled to announce a significant shift in our office model that will enhance our ability to attract top talent from across the USA, build a more flexible and sustainable culture, and – importantly – work from locations and time zones that are closer to our clients. Starting this year, we are transitioning…
We are excited to announce the release of our latest Environmental, Social, and Governance (ESG) report.
As HealthScience professionals, we spend a lot of time thinking about data. How many patients are there worldwide? How many days do these patients spend in hospital per year? How much more effective is drug X than drug Y? On Rare Disease Day, there are a lot of numbers to think about too. According to…
Graham Shelton, our Founder and Chairman, stepped down at the end of December 2024. We were proud to mark his retirement at our Oxford party, and present him with a book of memories from current and former colleagues and clients from around the world.
Revolutionizing pharma training: key takeaways from LTEN Unveiling the future of pharmaceutical training, we gathered invaluable insights at the Life Sciences Trainers & Educators Network (LTEN) Annual Conference. Training professionals are constantly striving for impactful learning experiences that not only educate, but also induce tangible behaviour change. Our Learning Design Team Lead, Jamie Singer, attended…
